We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Brain Cancer

Journal Scan / Research · January 10, 2022

Larotrectinib Is Safe and Effective in TRK Fusion–Positive Primary CNS Tumors



Additional Info

Disclosure statements are available on the authors' profiles:

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Neuro-oncology 2021 Nov 27;[EPub Ahead of Print], F Doz, CM van Tilburg, B Geoerger, M Højgaard, I Øra, V Boni, M Capra, J Chisholm, HC Chung, SG DuBois, S Gallego-Melcon, NU Gerber, H Goto, JE Grilley-Olson, JR Hansford, DS Hong, A Italiano, HJ Kang, K Nysom, A Thorwarth, J Stefanowicz, M Tahara, DS Ziegler, IT Gavrilovic, R Norenberg, L Dima, E De La Cuesta, TW Laetsch, A Drilon, S Perreault

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading